Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.
Identifieur interne : 000106 ( Ncbi/Merge ); précédent : 000105; suivant : 000107Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.
Auteurs : S. Callier [Canada] ; M. Morissette ; M. Grandbois ; T. Di PaoloSource :
- Synapse (New York, N.Y.) [ 0887-4476 ] ; 2000.
English descriptors
- KwdEn :
- 3,4-Dihydroxyphenylacetic Acid (metabolism), Animals, Carrier Proteins (analysis), Carrier Proteins (genetics), Carrier Proteins (metabolism), Corpus Striatum (chemistry), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Dopamine (deficiency), Dopamine (metabolism), Dopamine Plasma Membrane Transport Proteins, Estradiol (pharmacology), Gene Expression (drug effects), Homovanillic Acid (metabolism), MPTP Poisoning (drug therapy), MPTP Poisoning (metabolism), MPTP Poisoning (prevention & control), Male, Membrane Glycoproteins, Membrane Transport Proteins, Mice, Mice, Inbred C57BL, Nerve Tissue Proteins, Piperazines (metabolism), Piperazines (pharmacology), RNA, Messenger (analysis), Radioligand Assay, Receptors, Estrogen (metabolism), Substantia Nigra (chemistry), Substantia Nigra (drug effects), Substantia Nigra (metabolism), Tritium.
- MESH :
- chemical , analysis : Carrier Proteins, RNA, Messenger.
- chemical , deficiency : Dopamine.
- chemical , genetics : Carrier Proteins.
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Carrier Proteins, Dopamine, Homovanillic Acid, Piperazines, Receptors, Estrogen.
- chemistry : Corpus Striatum, Substantia Nigra.
- drug effects : Corpus Striatum, Gene Expression, Substantia Nigra.
- drug therapy : MPTP Poisoning.
- metabolism : Corpus Striatum, MPTP Poisoning, Substantia Nigra.
- chemical , pharmacology : Estradiol, Piperazines.
- prevention & control : MPTP Poisoning.
- Animals, Dopamine Plasma Membrane Transport Proteins, Male, Membrane Glycoproteins, Membrane Transport Proteins, Mice, Mice, Inbred C57BL, Nerve Tissue Proteins, Radioligand Assay, Tritium.
Abstract
Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17beta- and 17alpha-estradiol treatment (1 microg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17beta-estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17alpha-estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5-hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [(3)H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [(3)H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP-lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss.
DOI: 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5
PubMed: 10891861
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001618
- to stream PubMed, to step Curation: 001618
- to stream PubMed, to step Checkpoint: 001618
Links to Exploration step
pubmed:10891861Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.</title><author><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S" last="Callier">S. Callier</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec</wicri:regionArea><wicri:noRegion>Le Centre Hospitalier Universitaire de Québec</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M" last="Morissette">M. Morissette</name></author><author><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M" last="Grandbois">M. Grandbois</name></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10891861</idno><idno type="pmid">10891861</idno><idno type="doi">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</idno><idno type="wicri:Area/PubMed/Corpus">001618</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001618</idno><idno type="wicri:Area/PubMed/Curation">001618</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001618</idno><idno type="wicri:Area/PubMed/Checkpoint">001618</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001618</idno><idno type="wicri:Area/Ncbi/Merge">000106</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.</title><author><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S" last="Callier">S. Callier</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec</wicri:regionArea><wicri:noRegion>Le Centre Hospitalier Universitaire de Québec</wicri:noRegion></affiliation></author><author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M" last="Morissette">M. Morissette</name></author><author><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M" last="Grandbois">M. Grandbois</name></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name></author></analytic><series><title level="j">Synapse (New York, N.Y.)</title><idno type="ISSN">0887-4476</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term><term>Animals</term><term>Carrier Proteins (analysis)</term><term>Carrier Proteins (genetics)</term><term>Carrier Proteins (metabolism)</term><term>Corpus Striatum (chemistry)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Dopamine (deficiency)</term><term>Dopamine (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Estradiol (pharmacology)</term><term>Gene Expression (drug effects)</term><term>Homovanillic Acid (metabolism)</term><term>MPTP Poisoning (drug therapy)</term><term>MPTP Poisoning (metabolism)</term><term>MPTP Poisoning (prevention & control)</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Nerve Tissue Proteins</term><term>Piperazines (metabolism)</term><term>Piperazines (pharmacology)</term><term>RNA, Messenger (analysis)</term><term>Radioligand Assay</term><term>Receptors, Estrogen (metabolism)</term><term>Substantia Nigra (chemistry)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term><term>Tritium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Carrier Proteins</term><term>RNA, Messenger</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Carrier Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term><term>Carrier Proteins</term><term>Dopamine</term><term>Homovanillic Acid</term><term>Piperazines</term><term>Receptors, Estrogen</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Corpus Striatum</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Gene Expression</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>MPTP Poisoning</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Estradiol</term><term>Piperazines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Nerve Tissue Proteins</term><term>Radioligand Assay</term><term>Tritium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17beta- and 17alpha-estradiol treatment (1 microg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17beta-estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17alpha-estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5-hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [(3)H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [(3)H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP-lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10891861</PMID><DateCreated><Year>2000</Year><Month>09</Month><Day>14</Day></DateCreated><DateCompleted><Year>2000</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0887-4476</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Synapse (New York, N.Y.)</Title><ISOAbbreviation>Synapse</ISOAbbreviation></Journal><ArticleTitle>Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.</ArticleTitle><Pagination><MedlinePgn>245-51</MedlinePgn></Pagination><Abstract><AbstractText>Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17beta- and 17alpha-estradiol treatment (1 microg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17beta-estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17alpha-estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5-hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [(3)H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [(3)H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP-lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss.</AbstractText><CopyrightInformation>Copyright 2000 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Callier</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morissette</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grandbois</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Di Paolo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Synapse</MedlineTA><NlmUniqueID>8806914</NlmUniqueID><ISSNLinking>0887-4476</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>102-32-9</RegistryNumber><NameOfSubstance UI="D015102">3,4-Dihydroxyphenylacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>9J9974WIBA</RegistryNumber><NameOfSubstance UI="C044630">1-(2 (diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X77S6GMS36</RegistryNumber><NameOfSubstance UI="D006719">Homovanillic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015102" MajorTopicYN="N">3,4-Dihydroxyphenylacetic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006719" MajorTopicYN="N">Homovanillic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020267" MajorTopicYN="N">MPTP Poisoning</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="Y">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>13</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>13</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10891861</ArticleId><ArticleId IdType="pii">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</ArticleId><ArticleId IdType="doi">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name><name sortKey="Grandbois, M" sort="Grandbois, M" uniqKey="Grandbois M" first="M" last="Grandbois">M. Grandbois</name><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M" last="Morissette">M. Morissette</name></noCountry><country name="Canada"><noRegion><name sortKey="Callier, S" sort="Callier, S" uniqKey="Callier S" first="S" last="Callier">S. Callier</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000106 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000106 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10891861
|texte= Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10891861" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |